Riken Vitamin reported ordinary income of ¥4,209 million for the interim period of the fiscal year ending March 2027, 6.5% below the IFIS consensus of ¥4,500 million. Full-year ordinary income is forecast at ¥7,600 million, which is expected to be 12.6% below the IFIS consensus.
Riken Vitamin reported ordinary income of ¥4,209 million for the interim period of the fiscal year ending March 2027. The latest IFIS consensus was ¥4,500 million, making the result 6.5% below consensus.
In its full-year earnings forecast announced the same day, the company left ordinary income unchanged at ¥7,600 million, which is expected to be 12.6% below the IFIS consensus.